Cidara Therapeutics Inc’s filing revealed that its COO & CLO Ward Shane unloaded Company’s shares for reported $2.19 million on Dec 10 ’25. In the deal valued at $220.08 per share,9,959 shares were sold. As a result of this transaction, Ward Shane now holds 25,033 shares worth roughly $5.52 million.
Then, Davarpanah Nicole Negar sold 474 shares, generating $29,797 in total proceeds. Upon selling the shares at $62.86, the Chief Medical Officer now owns 31,418 shares.
Before that, RA CAPITAL MANAGEMENT, L.P. bought 2,272,727 shares. Cidara Therapeutics Inc shares valued at $99,999,988 were divested by the Director at a price of $44.00 per share. As a result of the transaction, RA CAPITAL MANAGEMENT, L.P. now holds 3,365,523 shares, worth roughly $742.6 million.
RBC Capital Mkts downgraded its Cidara Therapeutics Inc [CDTX] rating to a Sector perform from a an Outperform in a research note published recently. A number of analysts have revised their coverage, including Morgan Stanley’s analysts, who decreased its forecast for the stock in mid November from “an Overweight” to “an Equal-weight”. JP Morgan also remained covering CDTX and has decreased its forecast on November 17, 2025 with a “Neutral” recommendation from previously “an Overweight” rating. Morgan Stanley started covering the stock on October 16, 2025. It rated CDTX as “an Overweight”.
Price Performance Review of CDTX
On Friday, Cidara Therapeutics Inc [NASDAQ:CDTX] saw its stock jump 0.21% to $220.65. Over the last five days, the stock has gained 0.13%. Cidara Therapeutics Inc shares have risen nearly 895.26% since the year began. Nevertheless, the stocks have risen 720.87% over the past one year. While a 52-week high of $221.20 was reached on 12/03/25, a 52-week low of $15.22 was recorded on 04/07/25.
Levels Of Support And Resistance For CDTX Stock
The 24-hour chart illustrates a support level at 220.27, which if violated will result in even more drops to 219.90. On the upside, there is a resistance level at 220.90. A further resistance level may holdings at 221.16.
How much short interest is there in Cidara Therapeutics Inc?
A steep rise in short interest was recorded in Cidara Therapeutics Inc stocks on 2025-11-28, dropping by -1.09 million shares to a total of 2.11 million shares. Yahoo Finance data shows the prior-month short interest on 2025-10-31 was 3.2 million shares. There was a decline of -51.5%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on October 10, 2025 when JP Morgan began covering the stock and recommended ‘”an Overweight”‘ rating along with a $200 price target.
